Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in Vivo

Neoplasia

Volumn 13, Issue 5, 2011, Pages 483-491

  Rattan, Ramandeep ^a   Graham, Rondell P ^a   Maguire, Jacie L ^a   Giri, Shailendra ^a   Shridhar, Viji ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DENSITY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; MICROVASCULATURE; MITOSIS; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 79955834631     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11148     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, and Hartmann LC (2007). Current management strategies for ovarian cancer. Mayo Clin Proc 82, 751-770.
3. Gonzalez-Angulo AM and Meric-Bernstam F (2010). Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16, 1695-1700.
4. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, and Bost F (2010). Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9, 1092-1099.
5. Rattan R, Giri S, Hartmann L, and Shridhar V (2009).Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15, 166-178.
6. Reagan-Shaw S, Nihal M, and Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22, 659-661.
7. Shaw TJ, Senterman MK, Dawson K, Crane CA, and Vanderhyden BC (2004). Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10, 1032-1042.
8. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, and Pour PM (2001). Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270.
9. Algire C, Amrein L, Zakikhani M, Panasci L, and Pollak M (2010). Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17, 351-360.
10. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, et al. (2005). Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40, 685-693.
11. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, et al. (2008). Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99, 2136-2141.
12. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, and Bost F (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586.
13. Nagata D, Mogi M, and Walsh K (2003). AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 278, 31000-31006.
14. Phoenix KN, Vumbaca F, and Claffey KP (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113, 101-111.
15. Yun H, Lee M, Kim SS, and Ha J (2005). Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 280, 9963-9972.
16. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, and Randeva HS (2009). Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 83, 566-574.
17. Xavier DO, Amaral LS, Gomes MA, Rocha MA, Campos PR, Cota BD, Tafuri LS, Paiva AM, Silva JH, Andrade SP, et al. (2010). Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 64, 220-225.
18. Hwang YP and Jeong HG (2010). Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Cα-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol 160, 1195-1211.
19. Phoenix KN, Vumbaca F, Fox MM, Evans R, and Claffey KP (2010). Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123, 333-344.
20. Gotlieb WH, Saumet J, Beauchamp M-C, Gu J, Lau S, Pollak MN, and Bruchim I (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110, 246-250.
21. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, and Trajkovic V (2009). AMPK-mediated autophagy inhibits apoptosis in cisplatintreated tumour cells. J Cell Mol Med 13, 3644-3654.
22. Hirsch HA, Iliopoulos D, Tsichlis PN, and Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69, 7507-7511.